John A. Charlesworth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John A. Charlesworth has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Bruce A Pussell
Department of Nephrology, Prince of Wales Hospital and The University of New South Wales, Sydney, New South Wales, Australia
6 shared publications- Jonathan H. Erlich
University of New South Wales
2 shared publications - Philip W. Peake
Division of Medicine, Prince of Wales Hospital, Randwick, NSW 2031, Australia
2 shared publications Adamandia D. Kriketos
Diabetes Centre and the Garvan Institute of Medical Research, St Vincent's Hospital, Darlinghurst, New South Wales 2010, Australia
1 shared publicationCarol A Fenton‐Lee
Departments of Nephrology, Prince Henry and St. George Hospitals, University of New South Wales, Sydney, Australia
1 shared publicationCraig L Nelson
Department of Nephrology, Prince of Wales Hospital and University of New South Wales, Randwick, New South Wales, Australia
1 shared publication
Latest Publications
- 10 January 2008
- Published by Wiley in Nephrology
- Vol. 13 (1) , 45-50
Adult nephrotic syndrome: Non-specific strategies for treatment (Review Article)
Irrespective of aetiology, the nephrotic syndrome presents a range of potentially serious complications. These include thrombo-embolism, infection and hyperlipidaemia. Despite the prevalence of the nephrotic state among renal patients, there has been little prospective analysis of the therapeutic approach to these potentially life-threatening events even though their pathogenesis has been examined in some detail. Most of these complications are more prevalent once the albumin concentration falls below 20 g/L and it is recognized that restoration of serum albumin significantly diminishes their frequency. However, this may be difficult to achieve, especially in adults. The problems of thrombo-embolism and infection are of immediate concern but, in persistent cases, the additional issues of hyperlipidaemia and loss of bone density also require consideration for therapy. Thus, in addition to specific attempts to reduce proteinuria, it is recommended that high-risk nephrotic patients receive anticoagulation, pneumococcal vaccination and lipid lowering therapy. Strategies for the preservation of bone density should also be considered, particularly in patients who receive high-dose corticosteroids. Among a range of non-specific treatments for proteinuria, angiotensin-converting enzyme inhibitors appear best in terms of efficacy and safety. Prospective trials are required to clarify the longitudinal impact of these generic strategies on the protection of the persistently nephrotic patient.
- 10 January 2008
- Published by Wiley in Nephrology
- Vol. 13 (1) , 45-50
Adult nephrotic syndrome: Non-specific strategies for treatment (Review Article)
Irrespective of aetiology, the nephrotic syndrome presents a range of potentially serious complications. These include thrombo-embolism, infection and hyperlipidaemia. Despite the prevalence of the nephrotic state among renal patients, there has been little prospective analysis of the therapeutic approach to these potentially life-threatening events even though their pathogenesis has been examined in some detail. Most of these complications are more prevalent once the albumin concentration falls below 20 g/L and it is recognized that restoration of serum albumin significantly diminishes their frequency. However, this may be difficult to achieve, especially in adults. The problems of thrombo-embolism and infection are of immediate concern but, in persistent cases, the additional issues of hyperlipidaemia and loss of bone density also require consideration for therapy. Thus, in addition to specific attempts to reduce proteinuria, it is recommended that high-risk nephrotic patients receive anticoagulation, pneumococcal vaccination and lipid lowering therapy. Strategies for the preservation of bone density should also be considered, particularly in patients who receive high-dose corticosteroids. Among a range of non-specific treatments for proteinuria, angiotensin-converting enzyme inhibitors appear best in terms of efficacy and safety. Prospective trials are required to clarify the longitudinal impact of these generic strategies on the protection of the persistently nephrotic patient.
- Open Access
- 1 February 2006
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 21 (5) , 1427-1429
Acute granulomatous tubulointerstitial nephritis caused by intravesical BCG
A 72-year-old lady of Chinese ethnicity was referred because of an elevated plasma creatinine. She had a history of grade 3 transitional cell carcinoma (TCC) of the left ureter diagnosed 2 years previously. This had been treated by nephroureterectomy; the operative specimens showed widespread carcinoma in situ (CIS) involving the ureter, but the kidney and operative margins were free from malignancy. Recurrent grade 3, non-invading (T1) TCC and CIS of the bladder were detected on screening cystoscopy 3 months prior to referral. The tumour was treated by cauterization and a course of intravesical baccile Calmette–Guerin (BCG) was started for the CIS. Five weekly instillations of 81 mg of Connaught strain BCG were administered. No significant episodes of cystitis were noted during therapy. Serum creatinine had been 120 µmol/l since the time of nephrectomy until last measured 1 month prior to referral.
- 1 February 2006
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 21 (5) , 1427-1429
Open AccessAcute granulomatous tubulointerstitial nephritis caused by intravesical BCG
A 72-year-old lady of Chinese ethnicity was referred because of an elevated plasma creatinine. She had a history of grade 3 transitional cell carcinoma (TCC) of the left ureter diagnosed 2 years previously. This had been treated by nephroureterectomy; the operative specimens showed widespread carcinoma in situ (CIS) involving the ureter, but the kidney and operative margins were free from malignancy. Recurrent grade 3, non-invading (T1) TCC and CIS of the bladder were detected on screening cystoscopy 3 months prior to referral. The tumour was treated by cauterization and a course of intravesical baccile Calmette–Guerin (BCG) was started for the CIS. Five weekly instillations of 81 mg of Connaught strain BCG were administered. No significant episodes of cystitis were noted during therapy. Serum creatinine had been 120 µmol/l since the time of nephrectomy until last measured 1 month prior to referral.
- 1 June 2005
- Published by Elsevier in Metabolism
- Vol. 54 (6) , 821-828
Insulin resistance and postprandial triglyceride levels in primary renal disease
- 1 June 2005
- Published by Elsevier in Metabolism
- Vol. 54 (6) , 821-828
Insulin resistance and postprandial triglyceride levels in primary renal disease
- 1 February 2002
- Published by Wiley in Nephrology
- Vol. 7 (1) , 1-4
Vasculitic renal disease*
SUMMARY:The kidney may be involved in several forms of systemic vasculitis, particularly those affecting small‐calibre blood vessels. Hence, the majority of cases involve patients with Wegener's granulomatosis, Churg‐Strauss syndrome or microscopic polyangiitis. Anti‐neutrophil cytoplasmic antibodies (ANCA) are found in the majority of these patients and their detection has increased the sensitivity and specificity of diagnosis. However, the role of ANCA in the pathogenesis of these lesions remains uncertain. Moreover, the approach to treatment, both in terms of induction and maintenance of remission, remains problematic. This brief review discusses aspects of ANCA and current approaches to management.
- 1 February 2002
- Published by Wiley in Nephrology
- Vol. 7 (1) , 1-4
Vasculitic renal disease*
SUMMARY:The kidney may be involved in several forms of systemic vasculitis, particularly those affecting small‐calibre blood vessels. Hence, the majority of cases involve patients with Wegener's granulomatosis, Churg‐Strauss syndrome or microscopic polyangiitis. Anti‐neutrophil cytoplasmic antibodies (ANCA) are found in the majority of these patients and their detection has increased the sensitivity and specificity of diagnosis. However, the role of ANCA in the pathogenesis of these lesions remains uncertain. Moreover, the approach to treatment, both in terms of induction and maintenance of remission, remains problematic. This brief review discusses aspects of ANCA and current approaches to management.
- 1 August 2001
- Published by Wiley in Nephrology
- Vol. 6 (4) , 145-154
Complement in renal disease
- 1 June 2001
- Published by Wiley in Nephrology
- Vol. 6 (3) , 139
Plasma exchange therapy in rapidly progressive glomerulonephritis
- 1 June 2001
- Published by Wiley in Nephrology
- Vol. 6 (3) , 139
Plasma exchange therapy in rapidly progressive glomerulonephritis
- 28 June 1998
- Published by Wiley in Nephrology
- Vol. 4 (3) , 137-141
Expression of mesangial IgA nephropathy in a family with several HLA‐dentical members
- 28 June 1998
- Published by Wiley in Nephrology
- Vol. 4 (3) , 137-141
Expression of mesangial IgA nephropathy in a family with several HLA‐dentical members